Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results first posted: Jul 29, 2026
    • Primary endpoint revised
    • Enrollment target: 76 to 75
    • Secondary endpoint revised
    v31
  2. Trial status: Active, Not Recruiting to Completedv30 Show 4 more changesShow less
    • Enrollment target: estimated 75 to confirmed 76
    • Primary and study completion dates changed from estimate of Jul 2025 to Jun 11, 2025
    • Start date: Jul 2007 to Jul 10, 2007
    • Study site revised
  3. Primary and study completion dates: Jul 2024 to Jul 2025v29
  4. Primary and study completion dates: Jul 2023 to Jul 2024v28
  5. Re-verified, no change to tracked fieldsv27
Show 25 earlier versionsHide 25 earlier versions
  1. Primary and study completion dates: Jul 2022 to Jul 2023v26
  2. Primary and study completion dates: Jul 2021 to Jul 2022v25
  3. Primary and study completion dates: Jul 2020 to Jul 2021v24
  4. Primary and study completion dates: Jul 2019 to Jul 2020v23
  5. Primary and study completion dates: Jul 2018 to Jul 2019v22
  6. Primary and study completion dates: Jul 2017 to Jul 2018v21
  7. Re-verified, no change to tracked fieldsv20
  8. Primary and study completion dates: Jul 2016 to Jul 2017v19
  9. Primary and study completion dates: Jul 2015 to Jul 2016v18
  10. Primary and study completion dates: Jul 2014 to Jul 2015v17
  11. Re-verified, no change to tracked fieldsv16
  12. Primary and study completion dates: Jul 2012 to Jul 2014v15
  13. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v14
  14. Eligibility criteria expanded, about 3 wordsv13
  15. Primary and study completion dates: Jul 2011 to Jul 2012v12
  16. 2 versions Re-verified since Jul 15, 2010, no change to tracked fieldsv10-v11
  17. Primary and study completion dates: Jul 2010 to Jul 2011
    • Site contact updated
    v9
  18. Re-verified, no change to tracked fieldsv8
  19. Study description shortened, about 56 wordsv7
  20. Re-verified, no change to tracked fieldsv6
  21. Interventions: Immunizations (Biological), Immunizations (Biological) to Immunization Schedule patients > or = to 11 years of age (Biological), Immunization Schedule patients > or = to 7 years and <11 years of…
    • Study arms: 2 to 3
    v5
  22. Eligibility criteria expanded, about 28 wordsv4
  23. Primary completion date: Jul 2010
    • Eligibility criteria expanded, about 7 words
    v3
  24. Primary endpoint revisedv2 Show 4 more changesShow less
    • Study completion date: Jul 2010
    • Interventions: Pediarix, Diphtheria/tetanus +/- Acellular pertussis vaccine, IPOL®: , IPV,.Haemophilus influenza b conjugate vaccine,Recombinant Hepatitis… to Immunizations (Biological), Immunizations (Biological)
    • Secondary endpoint revised
    • Study arms: 0 to 2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standard way to re-immunize people after cancer treatments.
Trial Details
NCT Number NCT00505063
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions
(from sponsor)		 Childhood Cancer, Multiple Diseases
Related terms Neoplasms
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov